SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program

Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00114-9. doi: 10.1016/j.clml.2024.03.007. Online ahead of print.ABSTRACTChimeric antigen receptor T-cell (CAR-T) therapy has significantly impacted treatment algorithms and clinical outcomes for a variety of patients with hematologic malignancies over the past decade. The field of cellular immunotherapy is currently experiencing a rapid expansion of the number of patients eligible for CAR-T therapies as approvals are being seen in earlier lines of therapy. With the expanded patients eligible for these therapies, more treatment centers will be necessary to keep up with demand. Building a cellular therapy program can be a daunting task, and therefore, we present our experience with building a clinical cellular therapy program.PMID:38643029 | DOI:10.1016/j.clml.2024.03.007
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research